



## Press Release

### Panacea Medical Technologies Private Limited

October 07, 2019

#### Rating Reaffirmed & Assigned

<b>Total Bank Facilities Rated*</b>	Rs. 30.60 crore (Enhanced from Rs. 23.60 crore)
<b>Long Term Rating</b>	ACUITE BB+ / Outlook: Stable (Reaffirmed & Assigned)
<b>Short Term Rating</b>	ACUITE A4+ (Reaffirmed & Assigned)

\* Refer Annexure for details

#### Rating Rationale

Acuite has reaffirmed its long-term rating of '**ACUITE BB+**' (read as **ACUITE double B plus**) and short term rating of '**ACUITE A4+**' (read as **ACUITE A four plus**) on the Rs. 22.78 crore bank facilities of PANACEA MEDICAL TECHNOLOGIES PRIVATE LIMITED (PMTPL). The outlook is '**Stable**'.

Acuite has assigned long-term rating of '**ACUITE BB+**' (read as **ACUITE double B plus**) and short term rating of '**ACUITE A4+**' (read as **ACUITE A four plus**) on the Rs. 7.82 crore bank facilities of PMTPL. The outlook is '**Stable**'.

Incorporated in 1999, PMTPL was promoted by Mr. G.V Subramanyam. The company is engaged in the manufacturing of medical equipment for radiology and radiotherapy. It has tie-ups with Bhabha Atomic Research Centre (BARC) and Society for Applied Microwave Electronic Engineering and Research (SAMEER).

#### Analytical Approach

Acuite has considered the standalone view of business and financial risk profiles of PMTPL to arrive at this rating.

#### Key Rating Drivers

##### Strengths

- Established track record and experienced management**

PMTPL was incorporated in 1999. The Managing Director, Mr. Subramanyam, has experience of over three decades in the medical equipment industry. The company is also supported by other highly qualified and experienced Directors, Ms. Valli, Ms. Bala Deshpande, Mr. Tarun Sharma and Mr. Y. Ramann, with experience of more than two decades in the aforementioned line of business.

- Healthy financial risk profile**

The financial risk profile of the company is healthy marked by healthy net worth, low gearing, healthy debt protection metrics and coverage indicators.

The net worth of PMTPL is healthy, estimated at around Rs. 48.13 crore as on 31 March, 2019. The company has followed a conservative financial policy in the past, the same is reflected through its peak gearing and total outside liabilities to tangible net worth (TOL/TNW) levels of 0.33 times as on March 31, 2018 and 0.54 times as on March 31, 2018. The leverage levels continue to remain low at around 0.45 times as on March 31, 2019. PMTPL's healthy cash accruals to the tune of about Rs. 4.81 crore have also supported in minimizing the reliance on external debt, thereby leading to healthy gearing and absolute debt levels of 0.45 times and Rs. 21.61 crore as on March 31, 2019, respectively. The total debt of Rs. 21.61 crore as on 31 March, 2019 comprises of long-term borrowings of Rs. 12.56 crore from banks and research councils like Biotechnology Industry Research Assistance Council (BIRAC), Technology Development Board (TDB), unsecured loans of Rs. 0.07 crore and working capital borrowings to the tune of Rs. 8.98 crore. PMTPL's

cash accruals over the next two years through 2021 are estimated to remain in the range of Rs. 4.75 crore to Rs. 5.39 crore, which are adequate to service its repayment obligations and support its incremental working capital requirements to a certain extent.

The revenues of the company have gone up to Rs. 34.92 crore during FY2018-19 as against Rs. 28.08 crore in FY2017-18, and its operating margins are healthy at 21.21 per cent in FY2019. The low debt levels have led to healthy debt protection measures. The NCA/TD and interest coverage ratio for FY 2019 were healthy at 0.22 per cent and 4.68 times, respectively.

Acuite believes that the financial risk profile of PMTPL will continue to remain healthy over the near to medium term.

- **Reputed clientele along with moderate order book**

PMT has technological collaboration and support from major government agencies. The company has installed medical equipment in several hospitals including those run by the state government and charitable trusts. Further, PMT has moderate order book position marked by current orders-in-hand of Rs. 46.86 crore to be executed by September 2019, which leads to moderate revenue visibility over the medium term.

## **Weaknesses**

- **Moderate scale of operations and profitability**

PMTPL has modest scale of operations with the operating income of Rs. 34.92 crore for FY2019 as against Rs. 28.08 crore for FY2018. The revenue depends on the number of successful bids and tenders released by the government in the financial year. The operating margins (EBIDTA) stood at 21.21 per cent for FY2019 as against 15.35 per cent for FY2018. Further, the Profit after tax (PAT) margin stood at 11.33 per cent as against 4.94 per cent in FY2018.

- **Working capital intensive operations**

The operations of PMTPL are working capital intensive marked by high Gross Current Assets (GCA) of 591 days in FY2019 as against 746 days in FY2018. The high GCA days are mainly on account of high inventory holding of 282 days in FY2019 as against 295 days in FY2018. Out of the total inventory, there is certain portion of proto-type inventory as well. The prototype inventory is of new product and is expected to remain in the business for more than a year. The company has high debtors' days of 325 days as on 31 March, 2019 as against 358 days as on 31 March, 2018. The average working capital limit utilization has been more than 80 per cent in the last six months ended August 2019.

- **Exposure to foreign exchange fluctuations**

The company imports about 45 per cent (in FY2019) of raw material from various geographies and exports ~42 per cent (in FY2019) of its sales to developing countries. Thus, the company is exposed to forex fluctuation risk. However, the same is partly offset through natural hedging as the company maintains EEFC account and exports sales.

## **Rating Sensitivity Factor**

- Improvement in working capital operations (GCA days <300 days).
- Substantial improvement in scale of operation (~Rs. 50.00 crore to Rs. 55.00 crore), while maintaining profitability margin of around 18 to 20 per cent over the medium term.

## **Material covenants**

None

### Liquidity: Adequate

The company has adequate liquidity profile marked by moderate net cash accruals to its repayment obligations in the near term. The company generated cash accruals of Rs. 4.81 crore for FY2019, while its maturing debt obligations are around Rs. 2.16 crore for the same period. The cash accruals of the company are estimated to remain around Rs. 4.75 crore to Rs. 6.27 crore during FY2020-22 against repayment obligations of around Rs. 2.31 crore. PMTPL's working capital operations are intensive marked by gross current asset (GCA) of 591 days for FY2019. The company maintains unencumbered cash and bank balances of Rs. 0.76 crore as on 31 March, 2019. The current ratio stood low at 3.73 times as on 31 March, 2019. Acuite believes that the liquidity of the company is likely to remain adequate over the medium term on account of moderate cash accruals against debt repayments over the medium term.

### Outlook: Stable

Acuite believes that PMTPL will maintain a 'Stable' outlook and will continue to derive benefit over the medium term due to its 'extensive experience of promoters' and 'healthy financial risk profile'. The outlook may be revised to 'Positive', if the company demonstrates substantial and sustained growth in its revenues from the current levels while maintaining its capital structure. Conversely, the outlook may be revised to 'Negative' if the company generates lower-than-anticipated cash accruals, most likely as a result of sharp decline in operating margins, thereby impacting its financial risk profile, particularly its liquidity.

### About the Rated Entity - Key Financials

	Unit	FY19 (Actual)	FY18 (Actual)	FY17 (Actual)
Operating Income	Rs. Cr.	34.92	28.08	33.46
EBITDA	Rs. Cr.	7.41	4.31	5.31
PAT	Rs. Cr.	3.96	1.39	2.96
EBITDA Margin	(%)	21.21	15.35	15.88
PAT Margin	(%)	11.33	4.94	8.86
ROCE	(%)	11.00	6.70	11.21
Total Debt/Tangible Net Worth	Times	0.45	0.33	0.29
PBDIT/Interest	Times	4.68	3.14	2.53
Total Debt/PBDIT	Times	2.67	3.11	2.28
Gross Current Assets (Days)	Days	591	746	402

### Status of non-cooperation with previous CRA (if applicable)

Not Applicable

### Any other information

Not Applicable

### Applicable Criteria

- Default Recognition - <https://www.acuite.in/view-rating-criteria-17.htm>
- Financial Ratios And Adjustments - <https://www.acuite.in/view-rating-criteria-20.htm>
- Manufacturing Entities - <https://www.acuite.in/view-rating-criteria-4.htm>

### Note on complexity levels of the rated instrument

<https://www.acuite.in/criteria-complexity-levels.htm>

**Rating History (Up to previous three years)**

Date	Name of Instrument / Facilities	Term	Amount (Rs. Cr.)	Ratings/Outlook
February 18, 2019	Cash Credit	Long term	5.00	ACUITE BB+/ Stable (Downgraded from ACUITE BBB-/ Stable)
	Term Loans	Long term	1.10	ACUITE BB+/ Stable (Downgraded from ACUITE BBB-/ Stable)
	Term Loans	Long term	4.50	ACUITE BB+/ Stable (Downgraded from ACUITE BBB-/ Stable)
	Proposed Term Loans	Long term	4.00	ACUITE BB+/ Stable (Downgraded from ACUITE BBB-/ Stable)
	Bank Guarantee	Short Term	4.00	ACUITE A4+ (Downgraded from ACUITE A3)
	Letter of Credit	Short Term	5.00	ACUITE A4+ (Downgraded from ACUITE A3)
November 20, 2017	Bank Guarantee	Short Term	5.00	ACUITE A3 (Reaffirmed)
	Proposed letter of credit	Short Term	1.00	ACUITE A3 (Assigned)
	Cash Credit	Long term	5.00	ACUITE BBB-/ Stable (Reaffirmed)
	Term Loan	Long term	1.10	ACUITE BBB-/ Stable (Reaffirmed)
	Term Loan	Long term	2.40	ACUITE BBB-/ Stable (Withdrawn)
	Term Loan	Long term	4.50	ACUITE BBB-/ Stable (Assigned)
	Proposed Long Term Loan	Long term	3.00	ACUITE BBB-/ Stable (Assigned)
	Letter of Credit	Short Term	4.00	ACUITE A3 (Reaffirmed)
November 26, 2016	Cash Credit	Long term	5.00	ACUITE BBB-/ Stable (Assigned)
	Term Loan	Long term	1.10	ACUITE BBB-/ Stable (Assigned)
	Term Loan	Long term	2.40	ACUITE BBB-/ Stable (Assigned)
	Bank Guarantee	Short Term	3.00	ACUITE A3 (Assigned)
	Letter of Credit	Short Term	4.00	ACUITE A3 (Assigned)

**\*Annexure – Details of instruments rated**

Name of the Facilities	Date of Issuance	Coupon Rate	Maturity Date	Size of the Issue (Rs. Cr.)	Ratings/Outlook
Cash Credit	Not Applicable	Not Applicable	Not Applicable	5.00*	ACUITE BB+/ Stable (Reaffirmed)
Term Loan	Not Applicable	Not Applicable	Not Applicable	0.10	ACUITE BB+/ Stable (Reaffirmed)
Term Loan	Not Applicable	Not Applicable	Not Applicable	2.76	ACUITE BB+/ Stable (Reaffirmed)
Term Loan	Not Applicable	Not Applicable	Not Applicable	5.92	ACUITE BB+/ Stable (Reaffirmed)
Proposed Fund based facility	Not Applicable	Not Applicable	Not Applicable	1.82	ACUITE BB+/ Stable (Assigned)
Bank Guarantee	Not Applicable	Not Applicable	Not Applicable	4.00	ACUITE A4+ (Reaffirmed)
Letter of Credit	Not Applicable	Not Applicable	Not Applicable	5.00	ACUITE A4+ (Reaffirmed)
Proposed Non-fund based facility	Not Applicable	Not Applicable	Not Applicable	6.00	ACUITE A4+ (Assigned)

**Contacts**

Analytical	Rating Desk
Aditya Gupta Head- Corporate and Infrastructure Sector Ratings Tel: 022-49294041 <a href="mailto:aditya.gupta@acuите.in">aditya.gupta@acuите.in</a>  Charu Mahajan Analyst - Rating Operations Tel: 011-49731313 <a href="mailto:charu.mahajan@acuите.in">charu.mahajan@acuите.in</a>	Varsha Bist Manager - Rating Desk Tel: 022-49294011 <a href="mailto:rating.desk@acuите.in">rating.desk@acuите.in</a>

**About Acuite Ratings & Research:**

Acuite Ratings & Research Limited (erstwhile SMERA Ratings Limited) is a full-service Credit Rating Agency registered with the Securities and Exchange Board of India (SEBI). The company received RBI Accreditation as an External Credit Assessment Institution (ECAI), for Bank Loan Ratings under BASEL-II norms in the year 2012. Since then, it has assigned more than 6,000 credit ratings to various securities, debt instruments and bank facilities of entities spread across the country and across a wide cross section of industries. It has its Registered and Head Office in Mumbai.

**Disclaimer:** *An Acuité rating does not constitute an audit of the rated entity and should not be treated as a recommendation or opinion that is intended to substitute for a financial adviser's or investor's independent assessment of whether to buy, sell or hold any security. Acuité ratings are based on the data and information provided by the issuer and obtained from other reliable sources. Although reasonable care has been taken to ensure that the data and information is true, Acuité, in particular, makes no representation or warranty, expressed or implied with respect to the adequacy, accuracy or completeness of the information relied upon. Acuité is not responsible for any errors or omissions and especially states that it has no financial liability whatsoever for any direct, indirect or consequential loss of any kind arising from the use of its ratings. Acuité ratings are subject to a process of surveillance which may lead to a revision in ratings as and when the circumstances so warrant. Please visit our website ([www.acuite.in](http://www.acuite.in)) for the latest information on any instrument rated by Acuité.*